On the stock market since 2020, it operates in the world of health and science. It has 42 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 12 months, company executives reported 43 buys and 22 sells. Management buying with its own money is usually read as a good sign.
A loss of $30.1M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, VINCW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VINCW is a high-risk stock — not yet profitable, and its future rides on its product catching on.